Vestal Point Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Vestal Point Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-750,000	Closed	-$22.6M	–	100
2025 Q3	$22.6M	Buy	+750,000	New	+$22.5M	1.02%	37
2025 Q2	–	Sell	-500,000	Closed	-$18.1M	–	82
2025 Q1	$18.1M	Sell	500,000 -1,000,000	-67%	-$41.6M	1.29%	25
2024 Q4	$63.1M	Buy	1,500,000 +750,000	+100%	+$37.2M	3.74%	5
2024 Q3	$41.7M	Sell	750,000 -1,050,000	-58%	-$53.5M	3.16%	10
2024 Q2	$74M	Buy	1,800,000 +1,690,000	+1,536%	+$72.2M	5.52%	4
2024 Q1	$5.14M	Buy	+110,000	New	+$5.19M	0.42%	45

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vestal Point Capital's RARE Position: Q4 2025 in Review

Vestal Point Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 750,000 shares — an estimated $22.6M sold.

Vestal Point Capital first reported a position in RARE in Q1 2024 and held it in 6 quarters. The position peaked at $74M in Q2 2024. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Vestal Point Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Vestal Point Capital sold 750,000 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $22.6M.
Vestal Point Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 6 quarters.
Vestal Point Capital's Ultragenyx Pharmaceutical position peaked at $74M in Q2 2024.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.